Press Release: TZIELD® Phase 3 data presented at ISPAD

Press Release: TZIELD® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously published in The NEJM

TZIELD® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously published in The New England

Related Keywords

Paris , France General , France , Netherlands , Kevan Herold , Corentine Driancourt , Evan Berland , Tarik Elgoutni , Jose Eduardo Neves , Eva Schaefer Jansen , Felix Lauscher , Sandrine Guendoul , Nathalie Pham , Yale School Of Medicine , Nasdaq , Global Head Of Medical Affairs , Euronext , New England Journal , Long Professor , Yale School , Primary Investigator , Eduardo Neves , Vice President , Global Head , Medical Affairs , General Medicines , Provention Bio , Sanofi Company ,